Replies to post #86755 on Cytodyn Inc (CYDY)

[IndexGuy]

Sign me up for $53. I'll never get that far with more than half my current shares.

[Borel Fields]

Let's add Roche as a potential buyer. Actemra didn't do squat in coronavirus. In arthritis, it did well, but is past its peak. Their other immune drug, Xolair, faces that soon. A lot of people around with immunological backgrounds looking for something new to work on. Huge cancer franchise if they believe TNBC results. Big U.S. manufacturing ability for MABs through their Genentech unit. And with a $306B market cap, they could pay up.

[Venture_Cap]

I posted that awhile back. AZN is based in Delaware as well (wink to the recent 8k). AZN has been heavy in mab development.

$53 a share? Ok, but that’s just Covid and HIV market share. They would get cancer for free then.

Assuming a 1:1 swap. That’s low but I get it.

[RetiredandHappy]

I started reading this and I went this sure sounds familar. Nader wants $100/share.


AZN needs to throw in some comercial value certificates for potential phase 2 trials on the drawing board.

[mercurio]

0% chance they would do a 1 for 1 stock deal. CYDY closed at $4.48 today--why would anyone offer $53/share for a company whose stock closed at less than 10% of that?

If a buyout is presented, it will likely be in the $9-10 range. That's why a buyout would be an absolute travesty at this juncture.